OBM Genetics is an international Open Access journal published quarterly online by LIDSEN Publishing Inc. It accepts papers addressing basic and medical aspects of genetics and epigenetics and also ethical, legal and social issues. Coverage includes clinical, developmental, diagnostic, evolutionary, genomic, mitochondrial, molecular, oncological, population and reproductive aspects. It publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Publication Speed (median values for papers published in 2023): Submission to First Decision: 5.1 weeks; Submission to Acceptance: 17.0 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)

Current Issue: 2024  Archive: 2023 2022 2021 2020 2019 2018 2017

Special Issue

Molecular Cancer Therapeutics

Submission Deadline: May 01, 2019 (Closed) Submit Now

Guest Editor

Tapan K Bera, PhD

Senior Associate Scientist, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA

Website | E-Mail

Research Interests: antibody engineering; immunotherapy; recombinant immunotoxin; multiple myeloma; BCMA; mesothelin

About This Topic

Molecular Cancer Therapeutics is a special issue focused on articles related to the molecular basis of cancer, discovery and preclinical development of novel therapeutic agents for cancer and preclinical studies of approved therapeutics. Those includes identification of new genes that are specifically expressed in cancer, targeted therapy of cancer, the immunotherapy, and the study of small molecule and protein drugs. In this special issue of OBM Genetics, we aim to the introduction of the latest research progress and novel models and technologies in molecular cancer therapeutics. There is no limitation on the article types, original research papers, reviews, editorial, short communications, case reports and perspectives are welcome for submission. We sincerely welcome authors in this field to contribute their excellent works to this exciting forum.

Planed Papers

Title: Antibody-drug conjugates to treat negative breast cancer
Author: X. Margaret Liu

Title: Cardiomyocytes and the changes of the fuctionally determined spatial organization of ryanodin receptors during tumorgenesis
Author: Michael Hausmann

Title: IGF2 in physiology, cancer and cancer treatment
Author: Karoly Szuhai

Title: Clinical and molecular characteristics of biliary tract carcinoma using next-generation sequencing
Author: Antonio Cubillo Gracian

Title: Current progress on cancer immunotherapies using small molecules targeting PD-L1 stability
Author: Xiaolong Yang

Title: Interplay of Oncogenes and Their Immunosuppression in Gastric Cancer
Authors: Jiankang Jin, Xiaodan Yao, Shumei Song* and Jaffer A. Ajani*

Title: The use of Molecular techniques in diagnosis and therapy for patients
Author: Lampri Evangeli, et al

Title: A study on some calixpyrrole derivatives as potential cancer drugs
Authors: Franz Heinrich Kohnke, Camillo Rosano

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (genetics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!


Open Access Review

Molecular Mechanisms of Feline Cancers

Received: 08 December 2020;  Published: 24 May 2021;  doi: 10.21926/obm.genet.2102131


Feline cancers have not been studied as extensively as canine cancers, though they may offer similar advantages, with cats being immunocompetent animals subject to similar conditions as their human counterparts. The most common feline cancers include lymphoma, squamous cell carcinoma, sarcoma, and mammary tumors, though mast cell [...]
Open Access Original Research

Role of DNA Damage and MMP Loss in Radiosensitization-Induced Apoptosis by Ellagic Acid in HeLa Cells

Received: 22 September 2020;  Published: 14 May 2021;  doi: 10.21926/obm.genet.2102129


Ellagic acid (EA) is a polyphenol found in grapes, pomegranates, walnuts, etc. exhibits anti-cancer properties. The current study was conducted to understand the radiosensitizing role of EA on HeLa cells. Monotherapy of EA and radiation was initially studied on HeLa cells. The addition of EA before the radiation treatment subsequently made [...]
Open Access Review

Current Progress in Cancer Immunotherapies Using Small Molecules Targeting PD-L1 Stability

Received: 11 January 2021;  Published: 24 March 2021;  doi: 10.21926/obm.genet.2101127


PD-L1 is an immune checkpoint protein that is frequently overexpressed by the cells in the tumor microenvironment. PD-L1 binds to PD-1 present on the activated antitumor T-cells, which allows for tumor immune escape. The ability of the PD-1/PD-L1 axis to suppress antitumor immunity enables its application as a potential target for small-molecu [...]
Open Access Review

Oncogenes Orchestrate Immunosuppressive Stroma in Gastric Adenocarcinoma

Received: 30 June 2020;  Published: 16 September 2020;  doi: 10.21926/obm.genet.2003116


Gastric adenocarcinoma (GAC) is among the three most common cancers in the world. The majority of GAC patients are diagnosed in an advanced stage and have a median survival of ~9 months. There are limited effective therapeutic strategies available in the clinic and currently U.S. Food and Drug Administration (FDA) approved immune therapy is [...]
Open Access Review

Detection of Circulating Tumor DNA in Solid Tumors

Received: 27 May 2020;  Published: 06 August 2020;  doi: 10.21926/obm.genet.2003114


Cancer is characterized by sequential and progressive genetic and epigenetic alterations in key proto-oncogenes and tumor suppressor genes, which ultimately lead to tumor development. Advances in the technology of analysis of molecular mechanisms have increased the efficiency of clinical management of cancer patients. Recent years have witness [...]
Open Access Communication

Effective Delivery of Cancer Vaccines with Oxidatively Photo-Inactivated Transgenic Leishmania for Tumor Immunotherapy in Mouse Models

Received: 29 December 2019;  Published: 24 February 2020;  doi: 10.21926/obm.genet.2001103


The parasitic protozoa in the genus of Leishmania have exceptionally favorable attributes for exploitation as a vehicle for safe and effective delivery of transgenically incorporated vaccines against infectious and malignant diseases. A dual suicidal mechanism was installed in Leishmania via genetic and chemical engineering in vitro for accumu [...]
Open Access Review

Insulin-Like Growth Factor 2 in Physiology, Cancer, and Cancer Treatment

Received: 14 May 2019;  Published: 14 October 2019;  doi: 10.21926/obm.genet.1904096


IGF2 is a strongly mitogenic peptide and imprinted gene primarily involved in foetal development. In the foetus, IGF2 is highly expressed and is involved with foetal growth and tissue differentiation. However, postnatally IGF2 expression decreases although its expression level is still higher in blood than of IGF1. In adults, the physiological [...]
Open Access Communication

Upregulation of COX-2 in MCF7 Breast Cancer Cells When Exposed to Shear Stress

Received: 17 June 2019;  Published: 06 September 2019;  doi: 10.21926/obm.genet.1903092


Background: Invasive breast cancer affects 1 in 8 women in the United States and causes one of the highest cancer mortality rates for women. Cyclooxygenase-2 (COX-2), a central enzyme in prostaglandin biosynthesis, is implicated in breast cancer initiation, progression, invasion, metastasis, and has been implicated in mechanotransduction of [...]
Open Access Research Article

BSA-Embedded Carbonate Apatite Enhances Chemotherapeutic Effect of Paclitaxel in vitro and in vivo

Received: 29 March 2019;  Published: 15 August 2019;  doi: 10.21926/obm.genet.1903090


Among the strategies for enhanced pharmacokinetics and also pharmacodynamics of nano-formualtions is introduction of biocompatible materials to improve the capacity of the final product. With the aim to tackle drug loading and ultimate efficacy, incorporation of Bovine Serum Albumin (BSA) into carbonate apatite (CA) structure was applied in [...]
Open Access Review

Molecular Mechanisms of Canine Cancers

Received: 30 January 2019;  Published: 01 April 2019;  doi: 10.21926/obm.genet.1902071


Cancer is the leading cause of death in dogs, and 50 percent of dogs over the age of 10 develop cancer at some point. The most common cancers in dogs include lymphoma, mast cell tumors, osteosarcoma, mammary gland tumors, and melanoma, and many of these share marked similarities with their human counterparts. Although canines are afflicted [...]